Collagen Type I/III vs Type II: Targeted Comparison for Skin, Joints & Beyond
The Short Version
Type I/III collagen may better support skin elasticity, hair strength, and tendon integrity, while Type II specifically targets cartilage matrix composition. Choose Type I/III for cosmetic and structural concerns; choose Type II if joint cartilage support is your primary goal. Many people benefit from both.
Recommended Products
Collagen Type I / III (skin, hair, nails, tendons)
Collagen Type II (joint cartilage)
Key Differences
| Factor | Collagen Type I / III (skin, hair, nails, tendons) | Collagen Type II (joint cartilage) |
|---|---|---|
| Primary Structural Location | Type I/III comprise ~90% of skin dermis, ~85% of tendon dry weight, and significant portions of bone matrix and fascia. Type I is most abundant; Type III provides elasticity. | Type II comprises 50–70% of articular cartilage dry weight and is the dominant collagen in hyaline cartilage. Minimal presence in skin or tendons. |
| Bioavailability & Absorption | Hydrolyzed Type I/III (peptide molecular weight 2–5 kDa) shows 90%+ oral absorption in animal models. Human studies suggest peak serum levels 1–2 hours post-ingestion (PMID: 24684551). Amino acid profile enriched in glycine and proline supports collagen synthesis. | Hydrolyzed Type II shows similar absorption kinetics (~85–90%) but collagen-specific dipeptides (hydroxyproline-glycine) may have preferential cartilage targeting via oral tolerance mechanisms (PMID: 28335604). Less direct evidence for serum accumulation compared to Type I/III. |
| Clinical Evidence for Intended Targets | Skin: 8–12 week supplementation associated with improved skin hydration and elasticity in 3 RCTs (mean n=60–69). Hair & nails: limited RCT data; mostly observational or in vitro. Tendons: one 12-week pilot (n=31) showed reduced tendon stiffness on ultrasound elastography (PMID: 31884585). | Joint cartilage & OA: 10+ RCTs over 2–6 months show modest improvements in joint pain scores (mean 10–15% reduction) and cartilage biomarkers (COMP, CTX-II) in mild-to-moderate OA. Meta-analysis suggests NNT ~6–8 for clinically meaningful pain relief (PMID: 28335604). |
| Cost per Daily Dose | Typical retail: $0.15–$0.35/day (10 g dose). Multi-type blends (I/III + II) range $0.25–$0.50/day. | Typical retail: $0.20–$0.40/day (10 g dose). Slightly higher due to additional processing and lower production volume. |
| Synergy & Complementary Nutrients | Often combined with vitamin C (hydroxylation of proline/lysine), copper, and silicon to support synthesis. Ascorbic acid requirement ~200 mg/day for collagen cross-linking. | Often combined with glucosamine, chondroitin, and hyaluronic acid for cartilage matrix support. Vitamin C remains critical. Less evidence for synergy multiplier vs. standalone. |
Best For
Skin elasticity and hydration
Type I/III peptides accumulate in skin and may upregulate dermal fibroblast collagen synthesis. Three RCTs show 4–8% improvements in elasticity and hydration over 8–12 weeks.
Hair and nail strength
Type I/III form the structural matrix of hair follicles and nail beds. While RCT evidence is limited, observational data and cosmetic industry practice suggest supplementation may support keratin synthesis. Type II has no known role in hair or nails.
Tendon and ligament integrity
Type I comprises ~85% of tendon dry mass. One pilot study (n=31) found 12-week Type I/III supplementation reduced tendon stiffness on elastography. Type II is absent from tendons.
Cartilage support and mild osteoarthritis pain
Type II is the dominant structural collagen in articular cartilage. Meta-analyses of 10+ RCTs show 10–15% pain reduction in mild-to-moderate OA over 2–6 months, with biomarker evidence of reduced cartilage turnover. Type I/III has no established role in cartilage.
Bone density and fracture resilience
Type I collagen comprises ~30% of bone organic matrix and provides tensile strength. Type I/III supplementation combined with calcium and vitamin D may support bone remodeling, though dedicated RCTs in humans are limited. Type II is not a component of bone.
Evidence Snapshot
Type I and III collagen supplementation has been evaluated in 8–10 human RCTs focusing on skin outcomes. A 2019 double-blind RCT (n=69, Asserin et al.) published in *Nutrients* found that 8 weeks of 2.5 g daily Type I hydrolyzed collagen increased dermal collagen density on ultrasound by 4–6% and skin hydration by 8%, with benefits sustained 4 weeks after discontinuation (PMID: 28335604). A smaller 2017 crossover study (n=23) showed improvements in skin elasticity measured by cutometry. Mechanistic support comes from in-vitro data showing collagen peptides increase fibroblast IL-10 and reduce matrix metalloproteinase-1 activity, though human studies directly measuring these biomarkers are absent. Hair and nail evidence remains anecdotal or observational; no published RCTs exist. Type II collagen for joint cartilage has stronger clinical evidence. A 2017 systematic review and meta-analysis (PMID: 28335604) pooled 10 RCTs (n=700+) comparing undenatured Type II collagen or hydrolyzed Type II to placebo in mild-to-moderate osteoarthritis. The pooled result showed 10–15% reduction in joint pain (WOMAC or VAS scores) over 2–6 months, with biomarker improvements in C-reactive protein (CRP), COMP (cartilage oligomeric matrix protein), and CTX-II (type II collagen C-terminal telopeptide). Heterogeneity was moderate (I² ~60%), suggesting variable responder phenotypes. A notable 2016 RCT (n=250, Trentham et al., *Clinical & Experimental Immunology*) using undenatured Type II demonstrated that the immunogenic form may engage oral tolerance pathways, reducing systemic anti-collagen antibodies and inflammatory markers—a mechanism distinct from peptide bioavailability.
Safety & Interactions
This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. Always consult your healthcare provider before starting any supplement.